A Massachusetts-based biopharmaceutical company.

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to avoid prostate cancer recurrence Advantagene, Inc Click here ., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. The trial is expected to accrue 711 patients starting mid-2011 with definitive outcomes anticipated by 2015. The randomized research will evaluate ProstAtak’s capability to prevent prostate malignancy recurrence. If successful, it might yield the first medication product for diagnosed newly, localized prostate tumor. Prostate cancer may be the second most common reason behind death in American guys. Continue reading